Gregory P. Sargen
Independent DirectorMr. Gregory P. Sargen, also known as Greg, MBA, serves as Operating Partner at Altaris Capital Partners, LLC since joining the firm in August 2022. Mr. Sargen supports Altaris’ investment and portfolio company development activities in the pharmaceutical and pharma services sectors. He has been Director at Umoja BioPharma, Inc. since August 2021. He is Board Member of Kindeva Drug Delivery L.P. from March 2026. Mr. Sargen has been an Independent Director at Protara Therapeutics, Inc. (formerly known as Proteon Therapeutics Inc.) since January 2020. Mr. Sargen had been an Independent Director at ArTara Therapeutics, Inc. since November 2019 until January 2020. He served as Chief Financial Officer of Cambrex Corporation since September 4, 2018 until January 6, 2020. He served as Executive Vice President of Corporate Development & Strategy at Cambrex Corporation since January 20, 2017 until January 31, 2020. Mr. Sargen served as Chief Financial Officer of Cambrex Corporation from February 9, 2007 to January 20, 2017 and served as its Executive Vice President from January 2011 to January 20, 2017 and served as its Principal Accounting Officer until January 20, 2017. Mr. Sargen served as Vice President of Cambrex Corporation since February 2007 and served as its Vice President of Finance since February 2003. He has rare combination of broad financial experience, excellent business acumen and strong leadership skills. Mr. Sargen served as Vice President of Finance at Cambrex Corporation since February 2003. Prior to Cambrex, he served as Vice President of Finance - Chemicals Manufacturing Division of Fisher Scientific International Inc. (n/k/a Thermo Fisher Scientific Inc.). He served as an Executive Vice President for Finance, Chief Financial Officer, Vice President and Corporate Controller of Exp@nets, Inc. (Expanets) from 1999 to 2002. From 1996 to 1998, he served as Vice President of Finance and Controller of Fischer Scientific International's Chemical Manufacturing Division. He worked at Ernst & Young LLP. Mr. Sargen held various positions in finance, accounting and audit with Merck & Company, Inc., Heat and Control, Inc. and Deloitte & Touche LLP. He has extensive executive experience and has financial and accounting expertise with public companies in the CDMO industry. He had been an Independent Director of Avid Bioservices, Inc. since November 27, 2017 until February 05, 2025. He is Director of Kindeva Holdco L.P. Mr. Sargen holds an MBA degree in Finance from The Wharton School of the University of Pennsylvania and a B.S. in Accounting from Pennsylvania State University. Mr. Sargen is a Certified Public Accountant (non-practicing).
Positions
- Company NameProtara Therapeutics, Inc.Stock CodeTARAPositionIndependent DirectorColleagues
- JSJesse SheffermanCo-founder, CEO, President & Director
- LMLuke M. BesharIndependent Chairman of the Board
- JZJacqueline ZummoCo-Founder, Chief R&D Officer
- PFPatrick FabbioChief Financial Officer
- HFHannah FryVP, Principal Accounting Officer & Controller
- JOJustine O’MalleySenior Vice President of Investor Relations & Corporate Affairs
- CSCynthia SmithIndependent Director
- RJRoger J. GarceauIndependent Director
